CTLA4 and melanoma: Anti-Cytotoxic T-Lymphocyte Associated protein 4 (CTLA4) agents, such as ipilimumab represent a major class of drugs used in the treatment of incurable malignant melanoma, along with inhibitors of programmed cell death protein 1 (PD1) and programmed death ligand 11.